Medicinal cannabis for symptom control in advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of 1:1 tetrahydrocannabinol and cannabidiol

Abstract Purpose Patients with cancer commonly access cannabis hoping to relieve their symptoms. This study assessed whether a 1:1 10 mg/ml THC:CBD combination oil could improve

April 12, 2026

Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing

Abstract Objective: Evidence is accumulating that components of the Cannabis sativa plant may have therapeutic potential in treating psychiatric disorders. Medicinal cannabis (MC) products are legally available for

December 17, 2024

Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review

Abstract Background Medicinal cannabis has received increased research attention over recent years due to loosening global regulatory changes. Medicinal cannabis has been reported to have

November 15, 2023

Medicinal cannabis for patients with chronic non-cancer pain: analysis of safety and concomitant medications

Abstract Objectives This study aimed to explore the incidence of adverse events (AEs) reported by patients when initiating medicinal cannabis treatment for chronic pain, and

November 29, 2023

Medicinal Cannabis for Paediatric Developmental, Behavioural and Mental Health Disorders

Abstract Parents of children with developmental, behavioural and mental health disorders are increasingly asking whether medicinal cannabis might be a therapeutic option for their child.

September 5, 2024

Medicinal Cannabis for Emotional and Behavioural Symptoms: Parent and Physician Perspectives

January 31, 2026

Medicinal cannabis for chronic pain: The bermuda triangle of low-quality studies, countless meta-analyses and conflicting recommendations

Abstract The combination of the ongoing opioid crisis, inappropriateness of long-term use of NSAIDs, limited efficacy and tolerability of existing analgesics and the fact that

February 28, 2024

Medicinal cannabis for Australian patients with chronic refractory pain including arthritis

Abstract Objectives: To examine the tolerability and effectiveness of medicinal cannabis prescribed to patients for chronic, refractory pain, with a subset analysis on arthritis. Methods: This was

September 5, 2024

Medicinal cannabis extracts are neuroprotective against Aβ1–42-mediated toxicity in vitro

Abstract Background Phytocannabinoids inhibit the aggregation and neurotoxicity of the neurotoxic Alzheimer’s disease protein β amyloid (Aβ). We characterised the capacity of five proprietary medical

March 6, 2025

Medicinal Cannabis and the Intestinal Microbiome

Abstract Historically, the multiple uses of cannabis as a medicine, food, and for recreational purposes as a psychoactive drug span several centuries. The various components

April 3, 2025